KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Gains from Investment Securities: 2009-2024

Historic Gains from Investment Securities for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to $57.8 million.

  • Jazz Pharmaceuticals' Gains from Investment Securities rose 137.51% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.2 million, marking a year-over-year decrease of 51.42%. This contributed to the annual value of $57.8 million for FY2024, which is 13.35% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $57.8 million for FY2024, which was up 13.35% from $51.0 million recorded in FY2023.
  • Jazz Pharmaceuticals' 5-year Gains from Investment Securities high stood at $57.8 million for FY2024, and its period low was -$21.9 million during FY2020.
  • For the 3-year period, Jazz Pharmaceuticals' Gains from Investment Securities averaged around $51.4 million, with its median value being $51.0 million (2023).
  • Per our database at Business Quant, Jazz Pharmaceuticals' Gains from Investment Securities slumped by 215.83% in 2020 and then soared by 262.47% in 2021.
  • Over the past 5 years, Jazz Pharmaceuticals' Gains from Investment Securities (Yearly) stood at -$21.9 million in 2020, then surged by 262.47% to $35.6 million in 2021, then climbed by 27.64% to $45.4 million in 2022, then grew by 12.12% to $51.0 million in 2023, then climbed by 13.35% to $57.8 million in 2024.